Most of the patients with multiple myeloma are old and frail, as well as patients who have relapsed after multiple chemotherapy treatments. These patients are often weak and prone to complications of infection, and cannot tolerate high-dose chemotherapy or Vanco treatment, and simple Chinese medicine treatment is often unable to control the disease. In clinical practice, we have created a new treatment model: triple therapy, i.e. low-dose chemotherapy in the first month to control the tumor, arsenious acid in the second month to overcome drug resistance, and interferon + celecoxib in the third month to reverse the immune tolerance of the body, with different Chinese medicine treatments in different stages.